Financial Performance - The company's operating revenue for Q3 2021 reached ¥1,726,923,749.29, representing a year-on-year increase of 26.73%[4] - The net profit attributable to shareholders for Q3 2021 was ¥418,126,402.29, reflecting a significant increase of 52.16% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥390,607,833.15, up by 49.73% year-on-year[5] - Basic earnings per share for Q3 2021 were ¥0.471, an increase of 39.76% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 reached CNY 5,409,065,275.26, an increase of 25.4% compared to CNY 4,313,924,133.07 in the same period of 2020[19] - The net profit attributable to shareholders for the first three quarters of 2021 was CNY 4,822,290,155.24, compared to CNY 3,950,034,493.51 in 2020[18] - The net profit for the third quarter of 2021 was CNY 1,271,486,269.70, an increase of 32.4% compared to CNY 959,544,959.15 in the same period of 2020[21] - The total profit for the third quarter was CNY 1,473,047,507.51, up from CNY 1,112,072,115.97, reflecting a growth of 32.5% year-over-year[21] - The operating profit reached CNY 1,460,163,839.33, compared to CNY 1,095,371,896.98 in the previous year, marking a 33.3% increase[21] - Basic earnings per share for the third quarter were CNY 1.432, up from CNY 1.177, indicating a 21.6% increase[21] - The total comprehensive income for the third quarter was CNY 1,271,486,269.70, compared to CNY 959,544,959.15, reflecting a growth of 32.4%[22] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥11,464,670,298.49, which is a 9.02% increase from the end of the previous year[5] - The company's total liabilities were CNY 2,779,676,295.39, slightly up from CNY 2,752,651,384.65 in the previous year[16] - Total assets increased to CNY 11,464,670,298.49 as of September 30, 2021, compared to CNY 10,515,832,622.85 at the end of 2020[18] - Total liabilities were reported at RMB 2,752,651,384.65, with current liabilities at RMB 1,967,009,962.34[27] - Shareholders' equity totaled RMB 7,763,181,238.20, reflecting the company's strong capital position[28] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,595,160,443.44, showing an increase of 11.74% compared to the same period last year[5] - Cash flow from operating activities amounted to CNY 6,554,177,304.81, compared to CNY 5,418,145,966.76, representing a growth of 20.9%[22] - The company reported cash flow from investing activities of CNY 3,189,141,293.97, significantly higher than CNY 471,916,250.25 in the previous year[22] - The net cash flow from financing activities was negative at CNY -350,090,313.55, compared to a positive CNY 382,320,542.42 in the same quarter of 2020[23] - The cash and cash equivalents at the end of the period totaled CNY 4,085,296,933.46, an increase from CNY 3,857,176,213.45 at the end of the previous year[23] Costs and Expenses - Total operating costs for the same period were CNY 4,030,866,884.23, up 24.0% from CNY 3,248,952,251.35 in 2020[19] - Research and development expenses amounted to CNY 220,467,726.46, representing an increase of 20.5% from CNY 182,905,324.00 in the previous year[19] Company Strategy and Outlook - The company reported a significant increase in sales performance and effective cost control as the main reasons for profit growth[8] - The company has not disclosed any new product developments or market expansion strategies in this report[3] - The report indicates a stable financial outlook with a focus on maintaining asset growth and managing liabilities effectively[28]
济川药业(600566) - 2021 Q3 - 季度财报